SciELO - Scientific Electronic Library Online

 
vol.33 issue3The usefulness of intracellular adenosine-5'-triphosphate measurement in CD4+ cells in renal transplantAn unusual cause of glomerular hematuria and acute kidney injury in a chronic kidney disease patient during warfarin therapy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995

Abstract

FRANCISCO, Ángel L. M. de  and  RODRIGUEZ, Mariano. Magnesium - its role in CKD. Nefrología (Madr.) [online]. 2013, vol.33, n.3, pp.389-399. ISSN 1989-2284.  https://dx.doi.org/10.3265/Nefrologia.pre2013.Feb.11840.

Magnesium containing compounds present promising oral phosphate binders for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). However, the impact of magnesium in CKD patients still remains unclear in clinical routine practice. Therefore, this publication provides a practicable overview of knowledge about the physiological role of magnesium in general and in particular in CKD patients. Prevalence of hypomagnesaemia is high in the general population and especially in intensive care unit patients, but often not being detected. Magnesium deficiency increases the risk for several diseases, like diabetes mellitus type 2, hypertension and atherosclerosis. Moderate hypermagnesaemia, however, seems to have beneficial effects on vascular calcification and mortality rates in CKD patients. On the other hand, higher serum magnesium levels are reported to be linked to lower PTH levels and results on the effects on bone are controversial. In addition, low magnesium levels are associated with low bone mass, osteoporosis and vascular calcification. In dialysis patients serum magnesium levels are dependent mainly on the dialysate magnesium concentration. To confirm the potential delay of arterial calcification and improved survival outcomes by long-term intervention with magnesium powered randomized studies are required in dialysis patients. Since a recent trial revealed that a phosphate binder containing a combination of magnesium carbonate and calcium acetate was as effective as the polymer-based agent sevelamer hydrochloride and had an equally good tolerability profile, it is time for a re-examination of the role of magnesium in CKD patients.

Keywords : Magnesium; CKD; CKD-MBD; Phosphate; Phosphate binders; Hyperparathyroidism; Vascular calcification.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License